PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.

• K.-L. Koster,
• N.-M. Messerich,
• T. Volken,
• S. Cogliatti,
• T. Lehmann,
• A. Holbro,
• R. Benz,
• L. Graf,
• I. Demmer,
• W. Jochum,
• T. Silzle

Affiliations

K.-L. Koster

1 Clinic for Medical Oncology and Hematology

N.-M. Messerich

2 Departement of Intensive Care, Cantonal Hospital St. Gallen, St. Gallen

T. Volken

3 Institute of Public Health, ZHAW School of Health Sciences, Winterthur

S. Cogliatti

4 Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen

T. Lehmann

1 Clinic for Medical Oncology and Hematology

A. Holbro

5 Division of Hematology, University Hospital Basel, Basel

R. Benz

6 Clinic for Hematology and Oncology, Spital Thurgau AG, Münsterlingen

L. Graf

7 Centre for Laboratoty Medicine, St. Gallen, Switzerland

I. Demmer

4 Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen

W. Jochum

4 Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen

T. Silzle

1 Clinic for Medical Oncology and Hematology